The effect of near-infrared fluorescence conjugation on the anti-cancer potential of cetuximab

被引：1

作者：

Yun J.Y. ^{[1
,2
]}

Hyun B.-H. ^{[2
]}

Nam S.Y. ^{[1
]}

Yun Y.W. ^{[1
]}

Lee H.-J. ^{[3
]}

Lee B.-J. ^{[1
]}

机构：

[1] College of Veterinary Medicine and Research Institute of Veterinary Medicine, Chungbuk National University, 1 Chungdae-ro, Seowon-gu, Cheongju

[2] Laboratory Animal Center, Osong Medical Innovation Foundation, Cheongju

[3] College of Veterinary Medicine and Institute of Animal Medicine, Gyeongsang National University, 501 Jinjudae-ro, Jinju

来源：

Laboratory Animal Research | 2018年 / 34卷 / 1期

关键词：

A431; cells; Anti-cancer; Cetuximab-NIRF; near-infrared fluorescence;

D O I：

10.5625/lar.2018.34.1.30

中图分类号：

学科分类号：

摘要：

This study investigated the anti-cancer potential of a near-infrared fluorescence (NIRF) molecule conjugated with Cetuximab (Cetuximab-NIRF) in six-week-old female BALB/c athymic (nu+/nu+) nude mice. A431 cells were cultured and injected into the animals to induce solid tumors. Paclitaxel (30 mg/kg body weight (BW)), Cetuximab (1 mg/kg BW), and Cetuximab-NIRF (0.25, 0.5 and 1.0 mg/kg BW) were intraperitoneally injected twice a week into the A431 cell xenografts of the nude mice. Changes in BW, tumor volume and weight, fat and lean mass, and diameter of the peri-tumoral blood vessel were determined after two weeks. Tumor volumes and weights were significantly decreased in the Cetuximab-NIRF (1 mg/kg BW) group compared with the control group (P<0.001). Lean mass and total body water content were also conspicuously reduced in the Cetuximab-NIRF (1 mg/kg BW) group compared with the vehicle control group. Peri-tumoral blood vessel diameters were very thin in the Cetuximab-NIRF groups compared with those of the paclitaxel group. These results indicate that the conjugation of Cetuximab with NIRF does not affect the anti-cancer potential of Cetuximab and NIRF can be used for molecular imaging in cancer treatments. © 2018, The Author(s).

引用

页码：30 / 36

页数：6

共 32 条

[1]

Arteaga C.L., EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs, J Clin Oncol, 21, pp. 289s-291s, (2003)

[2]

Wheeler D.L., Dunn E.F., Harari P.M., Understanding resistance to EGFR inhibitors-impact on future treatment strategies, Nat Rev Clin Oncol, 7, 9, pp. 493-507, (2010)

[3]

Peng D., Fan Z., Lu Y., DeBlasio T., Scher H., Mendelsohn J., Anti- epidermal growth factor receptor monoclonal antibody 225 up- regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145, Cancer Res, 56, 16, pp. 3666-3669, (1996)

[4]

Fagin J.A., The Jeremiah Metzger lecture: intelligent design of cancer therapy: trials and tribulations, Trans Am Clin Climatol Assoc, 118, pp. 253-261, (2007)

[5]

Perrotte P., Matsumoto T., Inoue K., Kuniyasu H., Eve B.Y., Hicklin D.J., Radinsky R., Dinney C.P.N., Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice, Clin Cancer Res, 5, 2, pp. 257-265, (1999)

[6]

Petit A.M., Rak J., Hung M.C., Rockwell P., Goldstein N., Fendly B., Kerbel R.S., Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors, Am J Pathol, 151, 6, pp. 1523-1530, (1997)

[7]

Pepper C., Hoy T., Bentley D.P., Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance, Br J Cancer, 76, 7, pp. 935-938, (1997)

[8]

Wu X., Fan Z., Masui H., Rosen N., Mendelsohn J., Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin, J Clin Invest, 95, 4, pp. 1897-1905, (1995)

[9]

Ciardiello F., Bianco R., Damiano V., De Lorenzo S., Pepe S., De Placido S., Fan Z., Mendelsohn J., Bianco A.R., Tortora G., Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225, Clin Cancer Res, 5, 4, pp. 909-916, (1999)

[10]

Wild R., Fager K., Flefleh C., Kan D., Inigo I., Castaneda S., Luo F.R., Camuso A., McGlinchey K., Rose W.C., Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels, Mol Cancer Ther, 5, 1, pp. 104-113, (2006)

← 1 2 3 4 →